The stock has a 36-month beta value of 2.43. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BNGO is 68.47M, and at present, short sellers hold a 6.53% of that float. On August 12, 2024, the average trading volume of BNGO was 1.69M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BNGO) stock’s latest price update
The stock price of Bionano Genomics Inc (NASDAQ: BNGO) has plunged by -3.70 when compared to previous closing price of 0.39, but the company has seen a -27.16% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-07 that Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 nanochannel array flowcells in Q2 2024, which represents a 13% decrease from the number of flowcells sold in Q2 2023 The editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies Conference call today, August 7th, 2024 at 4:30 PM ET SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2024. “We saw positive growth in the OGM installed base this quarter, along with key advancements to our VIA software and the achievement of a significant milestone with the establishment of a Category I CPT code for OGM, which we believe will raise the awareness and utility of OGM,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.
BNGO’s Market Performance
Bionano Genomics Inc (BNGO) has experienced a -27.16% fall in stock performance for the past week, with a -42.11% drop in the past month, and a -60.35% drop in the past quarter. The volatility ratio for the week is 20.55%, and the volatility levels for the past 30 days are at 11.67% for BNGO. The simple moving average for the last 20 days is -34.50% for BNGO stock, with a simple moving average of -65.92% for the last 200 days.
Analysts’ Opinion of BNGO
Many brokerage firms have already submitted their reports for BNGO stocks, with Scotiabank repeating the rating for BNGO by listing it as a “Sector Outperform.” The predicted price for BNGO in the upcoming period, according to Scotiabank is $4 based on the research report published on January 05, 2023 of the previous year 2023.
BTIG Research, on the other hand, stated in their research note that they expect to see BNGO reach a price target of $3.50. The rating they have provided for BNGO stocks is “Buy” according to the report published on December 12th, 2022.
Oppenheimer gave a rating of “Outperform” to BNGO, setting the target price at $12 in the report published on July 18th of the previous year.
BNGO Trading at -44.66% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.98% of loss for the given period.
Volatility was left at 11.67%, however, over the last 30 days, the volatility rate increased by 20.55%, as shares sank -41.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.24% lower at present.
During the last 5 trading sessions, BNGO fell by -29.42%, which changed the moving average for the period of 200-days by -73.96% in comparison to the 20-day moving average, which settled at $0.5654. In addition, Bionano Genomics Inc saw -79.96% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -4.94 for the present operating margin
- 0.29 for the gross margin
The net margin for Bionano Genomics Inc stands at -5.58. The total capital return value is set at -1.96. Equity return is now at value -138.33, with -101.86 for asset returns.
Based on Bionano Genomics Inc (BNGO), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -4.03. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -35.49.
Currently, EBITDA for the company is -125.72 million with net debt to EBITDA at -0.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.06. The receivables turnover for the company is 5.76for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
To sum up, Bionano Genomics Inc (BNGO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
